Trial Profile

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selpercatinib (Primary)
Indications Advanced breast cancer; Colon cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; Expanded access
Acronyms LIBRETTO-201
Sponsors Loxo Oncology

17 Dec 2024 Status changed from recruiting to completed.
30 Mar 2023 Results evaluating EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib ,published in the Clinical Cancer Research
16 Jan 2023 Results assessing whether early initiation of selpercatinib is associated with decreased development of CNS metastases from the LIBRETTO-001 trial (NCT03157128) or the LIBRETTO-201 expanded access program (EAP, NCT03906331) trials, published in the Journal of Thoracic Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com